title: Effects of carvedilol on cardiomyocyte apoptosis and gene expression in vivo after ischemia-reperfusion in rats.
abstract: The effects of carvedilol on cardiomyocyte apoptosis and expression of bcl-2, bax genes following ischemia (0.5 h) and reperfusion (48 h) in vivo and the possible biological mechanism of carvedilol inhibiting cardiomyocyte apoptosis were studied. The left anterior descending artery in Wistar rats were ligated to establish ischemia-reperfusion (I/R) models. The model animals were divided into two groups: I/R group, the model rats not subject to other treatments except ischemia-reperfusion (n = 8); carvedilol-treated group (n = 8), I/R model rats treated with carvedilol. Eight rats in the sham-operated group were subjected to only experimental open operation. The number of apoptotic cardiomyocyte was determined by TUNEL staining. Immunohistochemistry and in situ hybridization histochemistry (ISHH) were used to detect the expression of bcl-2 and bax genes. Image processing system was used to quantitatively dispose the positive metric substances of both immunohistochemistry and ISHH through the average optical density (OD) value. The results showed that the number of the apoptotic cells were 36.18 +/- 9 (I/R group), 0-1 (sham-operated group) and 9.5 +/- 3 (carvedilol-treated group) in each visual field respectively with the difference being very significant among the groups (P < 0.001). The OD values of bcl-2 protein in sham-operated group, I/R group and carvedilol-treated group were 0.14 +/- 0.01, 0.08 +/- 0.02 and 0.15 +/- 0.03, respectively. The OD values of bcl-2 mRNA in sham-operated group, I/R group and carvedilol-treated group were 0.08 +/- 0.01, 0.06 +/- 0.01 and 0.09 +/- 0.01, respectively. There was no significant difference between carvedilol-treated group and I/R group (P > 0.05). The OD values of bax protein in I/R group, sham-operated and carvedilol-treated-treated group were 0.13 +/- 0.02, 0.07 +/- 0.01, 0.06 +/- 0.01, respectively. There was very significant difference between carvedilol-treated group and I/R group (P < 0.01). Bcl-2/bax ratio was 1.07 +/- 0.14 (I/R group), 1.28 +/- 0.16 (sham-operated group), 2.5 +/- 0.26 (carvedilol-treated group) respectively with the difference being very significant between carvedilol-treated group and I/R group (P < 0.05). It was indicated that carvedilol could inhibit cardiomyocyte apoptosis following ischemia and reperfusion, which was related to the increased bcl-2/bax ratio due to inhibition of bax gene expression.
authors.affiliation: Department of Cardiology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030.
authors.forename: Hesong
authors.initials: H
authors.lastname: Zeng
authors.forename: Xiaochun
authors.initials: X
authors.lastname: Liu
authors.forename: Huayue
authors.initials: H
authors.lastname: Zhao
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000818:Animals; D017209:Apoptosis / Q000187:drug effects*; D002227:Carbazoles / Q000494:pharmacology*; D000077261:Carvedilol; D015870:Gene Expression; D017202:Myocardial Ischemia / Q000235:genetics / Q000473:pathology; D015428:Myocardial Reperfusion Injury / Q000235:genetics / Q000473:pathology*; D032383:Myocytes, Cardiac / Q000473:pathology*; D011412:Propanolamines / Q000494:pharmacology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000378:metabolism; D011897:Random Allocation; D051381:Rats; D017208:Rats, Wistar; D051028:bcl-2-Associated X Protein
chemical_list: D000317:Adrenergic alpha-Antagonists; D000319:Adrenergic beta-Antagonists; C494828:Bax protein, rat; D002227:Carbazoles; D011412:Propanolamines; D011518:Proto-Oncogene Proteins; D019253:Proto-Oncogene Proteins c-bcl-2; D051028:bcl-2-Associated X Protein; D000077261:Carvedilol